• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 22
  • 17
  • 16
  • 6
  • 1
  • 1
  • Tagged with
  • 68
  • 68
  • 31
  • 25
  • 22
  • 20
  • 19
  • 19
  • 19
  • 18
  • 16
  • 12
  • 9
  • 9
  • 8
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
51

Rôle des lymphocytes NKT invariants humains dans régulation de la réponse alloimmune / Role Of Human Invariant NKT Lymphocytes In The Regulation Of The Alloimmune Response

Coman, Tereza 11 December 2015 (has links)
La survenue de la maladie du greffon contre l’hôte aiguë (GVHa) après l’allogreffe de cellules souches hématopoïétiques (CSH) reste une source majeure de mortalité et morbidité pour laquelle des avancées thérapeutiques restent indispensables. Les lymphocytes NKT invariants (iNKT) possèdent de multiples propriétés à potentiel immuno-régulateur et anti-tumoral, mais peu de données existent chez l’homme dans le cadre de l’allogreffe de CSH. Nous avons récemment montré qu’une bonne reconstitution en iNKT post greffe ainsi qu’une bonne richesse et capacité d’expansion des iNKT du greffon, notamment du sous type CD4-, étaient corrélés à une moindre survenue de GVHa chez les patients. Ce travail avait pour objectif de déterminer quel sous type de iNKT humain pouvait réguler la réponse allo-immune et ses mécanismes d’action. Dans le modèle murin humanisé de xéno-GVH, chez la souris NSG, nous avons mis en évidence que le sous-type iNKT CD4- humain ,contrairement au sous type CD4+, permettait de diminuer la survenue de GVH et d’améliorer la survie des souris NSG greffées avec des PBMC humains enrichis ou non en lymphocytes iNKT. Nous avons montré de façon concordante, in vivo et in vitro, que les iNKT CD4- humains diminuent le profil Th1 et Th17 des lymphocytes T conventionnels et leur marqueurs d’activation après stimulation allo- et xéno-génique. Par ailleurs, les iNKT CD4- humains induisent la mortalité des cellules dendritiques in vitro et in vivo, contrairement au sous-type iNKT CD4+ qui induit leur maturation. Par contre, les iNKT CD4- n’ont pas d’impact sur les lymphocytes T régulateurs, ni sur la prolifération des T conventionnels. Ils n’altèrent pas non plus la qualité de la prise de greffe des cellules humaines dans la souris NSG. Nous concluons, que contrairement aux iNKT murins, le sous-type iNKT CD4- humain, et non pas CD4+, est capable de diminuer la survenue de xéno-GVH dans le modèle murin NSG par une régulation directe de la réponse immune allogénique. Ces résultats obtenus dans ce modèle préclinique ouvrent la possibilité d’une nouvelle thérapie cellulaire utilisant ces cellules chez l’homme pour prévenir la survenue de GVH aiguë. / The occurrence of acute graft versus host disease (aGVHD) after allogeneic stem cell transplantation (allo-SCT) is a major source of mortality and morbidity and new therapeutic advances are urgently needed. Despite the numerous immunomodulatory properties depicted for the iNKT lymphocytes, there are few studies of these lymphocytes in human allo-SCT and GVHD setting. We previously reported that a higher iNKT reconstitution in patients after allo-SCT and higher graft CD4- iNKT expansion rates, were associated with reduced risk of aGVHD in patients. In this study we aimed to assess a direct immune regulatory role of CD4+ or CD4- iNKT subsets and their mechanisms of action during the allo-immune response. We demonstrated that the human iNKT CD4- subset, but not the CD4+ subset, was associated with reduced xeno-GVHD and prolonged survival of humanized NSG mice infused with human PBSC with or without iNKT cells. We also concomitantly showed, both in vitro and in vivo, that human iNKT CD4- could dampen Th1 and Th17 conventional T cell allo and xeno-responses as well as T cell activation markers. In addition, whereas iNKT CD4+ could stimulate DC maturation, iNKT CD4- induced their apoptosis, in vitro and in vivo. We did not observe any impact on regulatory T cells and conventional T cell proliferation. iNKT CD4- did not impact the engraftment of human cells in NSG mice. We conclude that, by contrast with mice, in humans, the CD4- subset and not their CD4+ counterpart can directly down-regulate the allo-immune response. These results obtained in a robust humanized preclinical xeno-GVH mice model could open new strategies of cellular therapy in the prevention of acute GVHD.
52

Cryopreservation of Induced Pluripotent Stem Cell Derived Neurons and Primary T-Cells and Natural Killer Cells Using Ice Recrystallization Inhibitor Technology

Alasmar, Salma 14 November 2022 (has links)
Given the rising demand for diverse cell types in regenerative and transfusion medicines, such as human induced pluripotent stem cell-derived neurons (iPSC-Ns), human T/chimeric antigen receptor (CAR) T cells, and human natural killer (NK) cells, the ability to cryopreserve cells has become increasingly important. In regenerative medicine, iPSC-Ns are powerful tools for treating and modelling neurodegenerative diseases. Moreover, transplants/transfusions of T/CAR T cells or NK cells offer promising treatment for numerous types of tumors, such as leukemia and multiple myeloma. Cryopreservation of cells at sub-zero temperatures (-80 to -196 °C) allows for the development of master cell banks that can be used for clinical applications. Conventional cryoprotective agents (CPAs), such as dimethylsulfoxide (DMSO) and glycerol, are utilized to protect cells from cryoinjuries associated with the freezing process. However, the use of high concentrations of DMSO (i.e., 10 to 20%) has been shown to be accompanied with toxic effects on patients receiving cell therapies if it is not removed or diluted prior to transfusion. Moreover, DMSO does not prevent the occurrence of the cryoinjury associated with ice recrystallization, which is one of the major causes of cell death/damage during cryopreservation. As a result, there is a surge of attention toward developing new non-toxic cryo-additives that inhibit ice recrystallization during cryopreservation to permit future advancement in regenerative and transfusion medicines. Moreover, the use of ice recrystallization inhibitors (IRIs) as novel CPAs has become a promising strategy to improve cell viability and function post-thaw. The Ben laboratory heavily invested in synthesizing several classes of carbohydrate-based small molecule IRIs (i.e., O-linked alkyl and aryl glycosides, and N-aryl-D-gluconamides), and studying the correlation between their IRI activity and molecular properties, such as polar surface area to molecular surface area (PSA/MSA) ratio. Moreover, compounds that belong to the O-linked aryl glycosides and N-aryl-D-gluconamides classes of IRIs have been shown to enhance the viability and functionality of red blood cells (RBCs), hematopoietic stem cells (HSCs), and induced pluripotent stem cells (iPSCs) after thawing. Part of the research presented throughout this thesis focuses on structure-activity relationship (SAR) studies of alkyl pyranoses with modified alkyl chain lengths to explore any correlations between the IRI activity and the net polarity (i.e., PSA/MSA ratio) of the IRI candidates. O- and C-linked alkyl pyranose derivatives with different alkyl chain lengths were synthesized and their IRI activity was assessed using the modified splat cooling assay. While the IRI activity of the O- and C-linked alkyl glucosides did differ as the length of the alkyl chain increased, no correlation between the PSA/MSA ratios and their IRI activity was observed. In addition, this work allowed for investigation into the effect of the type of the glycosidic bond (i.e., C-O and C-C bonds) at the anomeric position, on the IRI activity of the different compounds. The O-linked alkyl glucosides appeared to be more IRI active than the C-linked compounds, suggesting the nature of the glycosidic bond is important for IRI activity. The second part of the research presented in this thesis focuses on examining the potential for IRIs to cryopreserve iPSC-Ns, T/CAR T cells, and NK cells. 2-fluorophenyl-D-gluconamides (2FA), which is one of the most active IRIs from the N-aryl-Dgluconamides, has shown promising results in maintaining a high number of viable and functional HSCs and iPSCs post-thaw, and therefore it was employed in the cryopreservation protocol of iPSC-Ns, human-derived T/CAR T cells, and human-derived NK cells. The efficacy of the cryopreservation protocol being constructed was evaluated by assessing the post-thaw viability and recovery rate, as well as the functionality of iPSCNs, T/CAR T cells, and NK cells post-thaw. These studies showed that protecting against ice recrystallization during cryopreservation with IRIs increases the number of viable and functional iPSC-Ns, and T/CAR T cells. It was also observed that employing IRI technology in the cryopreservation protocol of NK cells does not compromise their functionality compared to fresh, non-frozen NK cells. Overall, inhibition of ice recrystallization using IRIs appeared to enhance the cryopreservation outcomes of the different cell types, which will allow for the development of off-the-shelf cell therapy products and improvement of the delivery of efficacious cell products to clinics and hospitals.
53

Altérations métaboliques et nature des acides gras : implication dans la différenciation des cellules régénératives du tissu adipeux

Lamontagne, Vikie 12 1900 (has links)
Par la sécrétion d’adipokines, le tissu adipeux blanc viscéral présent chez des patients souffrant d’obésité promeut l’installation d’altérations métaboliques telles que l’intolérance au glucose, la résistance à l’insuline et le diabète de type 2. Les complications cardiovasculaires, en particulier l’athérosclérose, sont les principales causes de mortalité chez les patients atteints de diabète de type 2. Il a été démontré que la fraction vasculaire stromale du tissu adipeux est composée de cellules régénératives dérivées du tissu adipeux (CRTA) et que ces cellules possèdent des caractéristiques des cellules progénitrices stromales (CPS). L’impact de l’intolérance au glucose et du diabète de type 2 sur les adipocytes sont assez bien documentés. Par contre, les conséquences de ces pathologies sur le comportement des CRTA n’ont pas été mesurées d’une façon approfondie. Plus particulièrement, l’impact de ces altérations métaboliques sur le potentiel de différenciation des CRTA en adipocytes et en cellules endothéliales n’a pas été étudié. Ce projet a pour but d’évaluer, dans un modèle murin, l’effet de ces altérations métaboliques sur l’équilibre de la différenciation in vitro des CRTA en adipocytes ou en cellules endothéliales. L’intolérance au glucose et le diabète de type 2 ont été induit chez les souris par la prise de deux diètes riches en acides gras de provenance végétale (DV) ou animale (DA). L’impact de l’origine des acides gras sur la différenciation des CRTA a également été étudié. Pour ce faire, une mise au point de la culture cellulaire des CRTA s’est avérée nécessaire et compte pour une partie de ces travaux de maîtrise. Nos travaux ont démontré en premier lieu, que le DMSO est un agent qui conserve la viabilité et les propriétés progénitrices des CRTA suite à leur congélation. De plus, parmi les matrices testées, le collagène s’est avéré être celle qui conserve le mieux les caractéristiques des progéniteurs et même, qui enrichie la population cellulaire ensemencée en cellules progénitrices. La densité cellulaire des cellules non-adipeuses du tissu adipeux s’avère être significativement plus élevée chez les souris du groupe de la DV comparativement aux souris contrôles. De plus, l’évaluation in vitro de la différenciation adipogénique démontre un potentiel de différenciation plus important pour les CRTA provenant des souris de la DV par rapport au groupe contrôle et à la DA. Cependant, la différenciation en cellules endothéliales est inhibée chez les CRTA de la DV, comparativement à un retard de ce processus pour la DA. Nos travaux suggèrent que le potentiel de différenciation adipogénique et endothéliale des CRTA est affecté par le statut métabolique des souris ainsi que par la nature de la diète. Ces résultats mettent en lumière pour la première fois l’importance d’évaluer le comportement des CRTA en fonction du statut métabolique du donneur, un paramètre pouvant avoir un impact majeur dans l’utilisation des CRTA autologues en thérapie cellulaire pour la réparation de tissus vasculaires chez des patients diabétiques. / The secretion of a large number of bioactive mediators by adipose tissue in abdominal obesity promotes metabolic diseases such as glucose intolerance, insulin resistance and type 2 diabetes. Cardiovascular complications, in particular atherosclerosis, are the leading causes of mortality in patients with type 2 diabetes. It has been shown that the stromal vascular fraction of adipose tissue comprised adipose-derived regenerative cells (ADRC) and that these cells possess progenitor cells characteristics. Effects of glucose intolerance and type 2 diabetes on adipocytes are well documented. However, consequences of these pathologies on ADRC behaviors are not well understood. Particularly, the impact of these metabolic alterations on the adipogenic and endothelial differentiation potential of ADRC has not been investigated. Aim of this project was to evaluate, in a murine model, the effect of these metabolic alterations on the balance of the in vitro ADRC differentiation into adipocytes or endothelial cells. Glucose intolerance and type 2 diabetes were induced in mice by the intake of two high-fat diets enriched in vegetal (VD) or animal (AD) fat. The impact of the fat origin on the ADRC differentiation was then evaluated. To do this, the development of cellular culture conditions of ADRC was necessary and an important part of this work. Our results suggest that DMSO is an efficient cryoprotective agent that conserves the viability and progenitor properties of ADRC following their freezing. Moreover, among tested scaffolds for the culture of ADRC, collagen is the best matrix to maintain progenitor characteristics and this matrix enriched the cellular population in progenitor cells. The cellular density of non-adipose cells fraction in the adipose tissue was significantly more elevated for VD mice than for the control group. The in vitro evaluation of adipogenic differentiation demonstrated an increase in the differentiation potential for ADRC from VD group compared to AD and control groups. In addition, the endothelial differentiation was abrogated for ADRC from VD group, compared to a delayed one for AD. These results suggest that the adipogenic and endothelial differentiation potential of ADRC and, consequently, the balance between emerging mature cells, are affected by the metabolic status of mice together with the nature of fatty acids. These results highlight, for the first time, the importance to evaluate the ADRC behavior in function to the metabolic status of donor, a parameter that could have an important impact in the use of autologous ADRC in cell-based therapy for the repair of injured vascular tissues in diabetic patients.
54

Development of cellular and gene therapies for b[beta]-Thalassemia and sickle cell disease

Felfly, Hady January 2008 (has links)
Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal.
55

Traitement de l'infarctus du myocarde chronique : contribution des cellules souches mésenchymateuses de moelle osseuse autologue / Treatment of chronic myocardial infarction : Impact of the bone marrow autologous mesenchymal stem cells

Maureira, Juan Pablo 18 December 2012 (has links)
La thérapie cellulaire et l'ingénierie tissulaire constituent de nouvelles stratégies à évaluer dans le traitement de la cardiopathie ischémique. Dans le cas particulier de l'infarctus chronique (IDMc), la possibilité de réhabiliter une zone cicatricielle à partir de cellules souches mésenchymateuses de moelle osseuse (CSMs), ainsi que la potentialité de remodeler l'architecture ventriculaire pariétale, sont particulièrement discutées. La première partie est un rappel des principaux concepts à l'origine des espoirs fondés sur ces nouvelles voies thérapeutiques. Dans la deuxième partie, nous présentons nos travaux concernant (1) l'injection cellulaire myocardique directe par voie épicardique chez le rat et chez l'homme souffrant d'IDMc et (2) l'application chirurgicale épicardique directe chez le rat IDMc, d'un patch tissulaire fabriqué à l'aide de CSMs incluses dans un réseau de collagène de type I. Les résultats montrent que l'injection cellulaire directe est responsable d'une réaction inflammatoire immédiate non spécifique. Néanmoins, ces travaux soutiennent aussi que (1) les CSMs stimulent l'angiogénèse locale en fonction de l'activité métabolique résiduelle et (2) le patch de CSMs favorise le remodelage ventriculaire inverse chez les rats infarcis. Dans la dernière partie, nous revenons, d'une manière plus générale, sur ces résultats qui restent encore trop limités pour espérer soigner une défaillance myocardique sévère. Néanmoins, bien que ces expériences ne confirment pas la potentialité cardiogénique des CSMs, elles suggèrent fortement la possibilité, par ces méthodologies, d'inverser le cours naturel de l'IDMc / Cellular therapy and tissue engineering are new strategies to be tested in the treatment of ischemic cardiopathy. In chronic infarction (MI) specifically, the possibility of rehabilitating a cicatricial zone using bone marrow mesenchymal stem cells (BMSC) as well as the feasibility of remodeling parietal ventricular architecture are especially discussed. The first part reviews the main concepts which have led to these new promising avenues of treatment. In the second part we present our work concerning (1) direct myocardial cellular injection via the epicardium in rats and in humans suffering from MI, and (2) direct epicardial surgical application of a tissular patch consisting of BMSC in a type I collagen network. The results show that direct cellular injection is responsible for an immediate non-specific inflammatory reaction. Nevertheless, the work also supports the notions that (1) BMSCs stimulate local angiogenesis on the basis of residual metabolic activity, and (2) the BMSC patch stimulates inverse ventricular remodeling in infarcted rats. The final part is devoted to a wider discussion of these results which are as yet too limited to hope to heal severe myocardial failure. However, despite the fact that these experiments do not confirm the cardiogenic potential of BMSCs, they do strongly hint at the possibility of using this methodology to invert the natural course of MI
56

Thérapie cellulaire en endoscopie interventionnelle digestive / Cellular therapy in digestive interventional endoscopy

Rahmi, Gabriel 27 November 2015 (has links)
Le développement récent de l’endoscopie interventionnelle digestive nous a conduit à prendre en charge deux types de pathologies préoccupantes. Il s’agit d’une part des fistules digestives souvent responsables d’une morbi-mortalité élevée et d’autre part des sténoses œsophagiennes après résection tumorale endoscopique étendue. Dans ces deux situations, des phénomènes inflammatoires chroniques conduisent soit à l’absence de fermeture de la fistule soit à une fibrose importante responsable de sténose de l’œsophage. La thérapie cellulaire a déjà été utilisée pour diminuer ces phénomènes inflammatoires et entrainer une cicatrisation. La thérapie tissulaire par cellules souches organisées en construction 3D représente un avantage important en permettant de cibler le site d’action par dépôt direct du feuillet cellularisé. Notre objectif était d’évaluer l’effet thérapeutique de ces nouveaux outils pour fermer les fistules digestives et pour prévenir la survenue des sténoses œsophagiennes. La première étape a consisté a évaluer l’efficacité du traitement par des cellules souches mésenchymateuses provenant de moelle osseuse humaine, marquées puis organisées en doubles feuillets, dans un modèle de fistule entéro-cutanée post-chirurgicale chez la souris nude. L’évaluation clinique et en imagerie (IRM et microscopie confocale) a montré une meilleure cicatrisation avec une augmentation de la microvascularisation et une accélération de la fermeture de la fistule chez les souris greffées. Les effets observés semblent liés à une augmentation précoce de la synthèse des facteurs de réparation (EGF et le VEGF) et des cytokines anti-inflammatoires (TGF-ß2 et IL-10). Après avoir développé un modèle inédit de fistule oeso-cutanée chez le porc grâce à la mise en place par voie endoscopique et chirurgicale de prothèses plastiques entre la lumière œsophagienne et la peau, nous avons évalué l’efficacité thérapeutique d’un gel contenant des vésicules extracellulaires issues de cellules souches isolées du tissu adipeux de porc. Ce gel injecté dans la fistule par voie endoscopique a permis la fermeture des fistules. Enfin, la troisième partie de notre travail a consisté à évaluer l’efficacité de la greffe allogénique de doubles feuillets de cellules souches mésenchymateuses pour prévenir la survenue des sténoses œsophagiennes dans un modèle porcin après dissection sous muqueuse étendue. Il existait une réduction significative du taux de sténose œsophagienne cicatricielle dans le groupe greffé avec une fibrose moins importante. En conclusion, l’effet paracrine antifibrosant des cellules souches mésenchymateuses organisées en feuillets est efficace à la fois pour fermer les fistules entéro-cutanées chez la souris et pour prévenir les sténoses œsophagiennes chez le porc. Un gel avec des vésicules extracellulaires issues des cellules souches a de la même façon un effet cicatrisant anti-inflammatoire permettant la fermeture des fistules œsophagiennes chez le porc. Ces résultats sont très encourageants et posent la question d’une évaluation future chez l’homme. / Recent developments in digestive interventional endoscopy lead us to manage two types of digestive disease. First, it is digestive fistulas associated in many cases with high morbi-mortality; and second is oesophageal stenosis after extended superficial endoscopic resection. In both situations, chronic inflammatory process resulted in delayed or no fistula healing for the first case or oesophageal stenosis due to fibrosis. Cellular therapy has proved to be successful in reducing the inflammatory process and to promote tissue healing. Tissue therapy with 3D construct stem cells represents a major advantage by allowing a direct adaptation on the right place. Our objective was to evaluate the therapeutic effect of new strategy to close the digestive fistula and to prevent oesophageal stenosis. First step was to evaluate the effect of labelled human bone marrow derived mesenchymal stem cells engraftment in the form of double cellsheet in a post-surgical fistula model in nude mice. Clinical and radiological (MRI and probe based confocal microscopy) evaluation showed a better fistula healing with higher microvascularization and a faster fistula closing in grafted mice. These effects appear to be related to an increase production of factors involved in tissue repair (EGF et le VEGF) and anti-inflammatory cytokines (TGF-ß2 et IL-10). We developed an unpublished eso-cutaneous fistula in a porcine model after plastic catheters placement by surgical and endoscopic way between the oesophageal lumen and the skin. We evaluated the therapeutic effect of a hydrogel with extracellular vesicles extracted from porcine adipose derived stem cells. The hydrogel with vesicles was injected into the fistula by endoscopy. Radiological and histological evaluation 15 days after injection showed a fistula tract closure in treated group.The third part of this work was to evaluate the effect of allograft of adipose derived stem cells 3D construct to prevent the stenosis after extended endoscopic submucosal dissection in a porcine model. There was a significant reduction of number and degree of stenosis with decrease fibrosis infiltration in the grafted group.In summary, thanks to their paracrine and antifibrotic effect, the mesenchymal stem cells organised as 3D construct allowed fistula closure in an entero-cutaneous model in mice and prevention of stenosis after extended oesophageal submucosal dissection in a porcine model. Moreover, endoscopic hydrogel and extracellular vesicles injection allowed oesophageal fistula healing in a porcine model. These promising results pose the challenge of future clinical studies.
57

Efeito das células derivadas da medula óssea no tratamento da insuficiência renal crônica experimental.

Caldas, Heloisa Cristina 26 July 2011 (has links)
Made available in DSpace on 2016-01-26T12:51:30Z (GMT). No. of bitstreams: 1 heloisacaldas_tese.pdf: 13961449 bytes, checksum: adc041656d053c466bd2f0851119388c (MD5) Previous issue date: 2011-07-26 / Chronic renal failure (CRF) is characterized by progressive and irreversible loss of renal function and its treatment generates significant public spending for maintenance and care of patients on dialysis. Stem cell (SC) therapy, in its potential for treatment of chronic diseases, may be a promising strategy for repairing the damage from or slowing the progression of CRF. There are questions about cell type, quantity of cells, method and ideal place for deployment of SC and the role it plays in the repair of renal parenchyma. Objective: 1) To evaluate the effect of infusion of bone marrow derived cells (BMDC) in the treatment of experimental CRF; 2) Evaluate the combined effect of SC and biomaterial (BM) in the progression of CRF and study the effect of this therapy in different stages of CRF; 3) Evaluate the development of techniques for isolation and cultivation of human umbilical cord blood (HUCB) mesenchymal cells. Methods: Article 1: We used the 5/6 mass reduction model to induce experimental CRF. Kidney function was measured at the beginning of the experiment and 60 and 120 days after the surgery; Article 2: Animals were subdivided as to the amount of renal parenchyma injured (5/6 or 2/3), the use of BM as a scaffold to cell implantation, and cell type used (mononuclear or mesenchymal cells). Renal function was evaluated on days 0, 45, and 90 after surgery. Histological and immunohistochemical analyses were done in all groups at the end of the study; Article 3: Ten samples of HUCB were used and two different procedures for cultivation of mesenchymal stem cells (MSC) were tested: without Ficoll-Paque density gradient, to obtain nucleated cells; with Ficoll-Paque density gradient, for obtaining mononuclear cells. Results: Article 1: CRF progression analysis showed that treatment with BMDC significantly reduced the rate of decline of creatinine clearance (Clcr) when compared with the control group; Article 2:Treated animals showed significantly lower increases in serum creatinine and 24 hour proteinuria, and higher increases in Clcr after 90 days when compared to control animals in both models of CRF; Article 3: The MSC in culture from the method without Ficoll-Paque density gradient maintained growth forming confluent cell foci. Conclusions: Article 1: Progression of CRF can be delayed by injection of BMDC in the renal parenchyma; Article 2: a) Use of SC combined with BM can be an alternative way to administer BMDC; b) Cell therapy seems to be most effective when administered in less severe stages of CRF; Article 3: Nucleated cells without using Ficoll-Paque density gradient showed more efficiency in the cultivation of MSC from HUCB when compared with the procedure employing Ficoll-Paque density gradient / A insuficiência renal crônica (IRC) é caracterizada pela perda progressiva e irreversível da função renal e seu tratamento gera um gasto público significativo para manutenção de pacientes em tratamento dialítico. A terapia com células-tronco (CT), pelo seu potencial de tratamento das doenças crônicas, pode ser uma estratégia promissora para reparar ou retardar a progressão da IRC. Existem dúvidas sobre o tipo celular, a quantidade de células, o método e local ideal para implantação das CT e o papel por elas desempenhado na reparação do parênquima renal. Objetivos: 1) avaliar o efeito da infusão de células derivadas da medula óssea (CDMO) no tratamento da IRC experimental; 2) avaliar o efeito combinado das CT e biomaterial (BM) na progressão da IRC e estudar o efeito dessa terapia em diferentes estágios da IRC; 3) Avaliar o desenvolvimento de técnicas de isolamento e cultivo de células mesenquimais do sangue de cordão umbilical humano (SCU). Métodos: artigo 1: usamos o modelo de redução de massa 5/6 para induzir a IRC experimental. Função renal foi medida no início do experimento e 60 e 120 dias depois da cirurgia; artigo 2: animais foram subdivididos conforme a quantidade de parênquima renal lesado (5/6 ou 2/3), o uso de BM como arcabouço para o implante celular e o tipo de células utilizado (célula mononuclear ou mesenquimal). A função renal foi avaliada nos dias 0, 45 e 90 após cirurgia. Análise histológica e imunohistoquimica foram realizadas em todos os grupos ao final do estudo; artigo 3: Foram utilizadas dez amostras de SCU e testados dois diferentes procedimentos para cultivo de células-tronco mesenquimal (CTM): sem gradiente de densidade Ficoll-Paque, para obtenção de células nucleadas; por gradiente de densidade Ficoll-Paque, para obtenção de células mononucleares. Resultados: artigo 1: Análises da progressão da IRC mostraram que o tratamento com CDMO reduziu significativamente a taxa de declínio do clearance ( Clcr) quando comparados com o grupo controle; artigo 2: animais tratados apresentaram aumentos significativamente menores de creatinina sérica, proteinúria e Clcr maiores após 90 dias, quando comparado aos animais controles em ambos os modelos de IRC; artigo 3: as CTM em cultura provenientes do método sem gradiente de densidade Ficoll- Paque mantiveram o crescimento formando focos confluentes de células. Conclusões: artigo 1: a progressão da IRC pode ser retardada pela injeção de CDMO no parênquima renal; artigo 2: a) utilização da CT combinada com o BM pode ser uma via alternativa para administrar a CTMO; b) terapia celular parece ser mais eficaz quando administrada em estágios menos graves da IRC; artigo 3: As células nucleadas sem uso do gradiente de densidade Ficoll-Paque mostraram mais eficiente para o cultivo de CTM do SCU quando comparado ao procedimento com gradiente de densidade Ficoll-Paque.
58

Altérations métaboliques et nature des acides gras : implication dans la différenciation des cellules régénératives du tissu adipeux

Lamontagne, Vikie 12 1900 (has links)
Par la sécrétion d’adipokines, le tissu adipeux blanc viscéral présent chez des patients souffrant d’obésité promeut l’installation d’altérations métaboliques telles que l’intolérance au glucose, la résistance à l’insuline et le diabète de type 2. Les complications cardiovasculaires, en particulier l’athérosclérose, sont les principales causes de mortalité chez les patients atteints de diabète de type 2. Il a été démontré que la fraction vasculaire stromale du tissu adipeux est composée de cellules régénératives dérivées du tissu adipeux (CRTA) et que ces cellules possèdent des caractéristiques des cellules progénitrices stromales (CPS). L’impact de l’intolérance au glucose et du diabète de type 2 sur les adipocytes sont assez bien documentés. Par contre, les conséquences de ces pathologies sur le comportement des CRTA n’ont pas été mesurées d’une façon approfondie. Plus particulièrement, l’impact de ces altérations métaboliques sur le potentiel de différenciation des CRTA en adipocytes et en cellules endothéliales n’a pas été étudié. Ce projet a pour but d’évaluer, dans un modèle murin, l’effet de ces altérations métaboliques sur l’équilibre de la différenciation in vitro des CRTA en adipocytes ou en cellules endothéliales. L’intolérance au glucose et le diabète de type 2 ont été induit chez les souris par la prise de deux diètes riches en acides gras de provenance végétale (DV) ou animale (DA). L’impact de l’origine des acides gras sur la différenciation des CRTA a également été étudié. Pour ce faire, une mise au point de la culture cellulaire des CRTA s’est avérée nécessaire et compte pour une partie de ces travaux de maîtrise. Nos travaux ont démontré en premier lieu, que le DMSO est un agent qui conserve la viabilité et les propriétés progénitrices des CRTA suite à leur congélation. De plus, parmi les matrices testées, le collagène s’est avéré être celle qui conserve le mieux les caractéristiques des progéniteurs et même, qui enrichie la population cellulaire ensemencée en cellules progénitrices. La densité cellulaire des cellules non-adipeuses du tissu adipeux s’avère être significativement plus élevée chez les souris du groupe de la DV comparativement aux souris contrôles. De plus, l’évaluation in vitro de la différenciation adipogénique démontre un potentiel de différenciation plus important pour les CRTA provenant des souris de la DV par rapport au groupe contrôle et à la DA. Cependant, la différenciation en cellules endothéliales est inhibée chez les CRTA de la DV, comparativement à un retard de ce processus pour la DA. Nos travaux suggèrent que le potentiel de différenciation adipogénique et endothéliale des CRTA est affecté par le statut métabolique des souris ainsi que par la nature de la diète. Ces résultats mettent en lumière pour la première fois l’importance d’évaluer le comportement des CRTA en fonction du statut métabolique du donneur, un paramètre pouvant avoir un impact majeur dans l’utilisation des CRTA autologues en thérapie cellulaire pour la réparation de tissus vasculaires chez des patients diabétiques. / The secretion of a large number of bioactive mediators by adipose tissue in abdominal obesity promotes metabolic diseases such as glucose intolerance, insulin resistance and type 2 diabetes. Cardiovascular complications, in particular atherosclerosis, are the leading causes of mortality in patients with type 2 diabetes. It has been shown that the stromal vascular fraction of adipose tissue comprised adipose-derived regenerative cells (ADRC) and that these cells possess progenitor cells characteristics. Effects of glucose intolerance and type 2 diabetes on adipocytes are well documented. However, consequences of these pathologies on ADRC behaviors are not well understood. Particularly, the impact of these metabolic alterations on the adipogenic and endothelial differentiation potential of ADRC has not been investigated. Aim of this project was to evaluate, in a murine model, the effect of these metabolic alterations on the balance of the in vitro ADRC differentiation into adipocytes or endothelial cells. Glucose intolerance and type 2 diabetes were induced in mice by the intake of two high-fat diets enriched in vegetal (VD) or animal (AD) fat. The impact of the fat origin on the ADRC differentiation was then evaluated. To do this, the development of cellular culture conditions of ADRC was necessary and an important part of this work. Our results suggest that DMSO is an efficient cryoprotective agent that conserves the viability and progenitor properties of ADRC following their freezing. Moreover, among tested scaffolds for the culture of ADRC, collagen is the best matrix to maintain progenitor characteristics and this matrix enriched the cellular population in progenitor cells. The cellular density of non-adipose cells fraction in the adipose tissue was significantly more elevated for VD mice than for the control group. The in vitro evaluation of adipogenic differentiation demonstrated an increase in the differentiation potential for ADRC from VD group compared to AD and control groups. In addition, the endothelial differentiation was abrogated for ADRC from VD group, compared to a delayed one for AD. These results suggest that the adipogenic and endothelial differentiation potential of ADRC and, consequently, the balance between emerging mature cells, are affected by the metabolic status of mice together with the nature of fatty acids. These results highlight, for the first time, the importance to evaluate the ADRC behavior in function to the metabolic status of donor, a parameter that could have an important impact in the use of autologous ADRC in cell-based therapy for the repair of injured vascular tissues in diabetic patients.
59

Development of cellular and gene therapies for b[beta]-Thalassemia and sickle cell disease

Felfly, Hady January 2008 (has links)
Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal
60

PHARMACOLOGICAL TARGETING OF FGFR SIGNALING TO INHIBIT BREAST CANCER RECURRENCE AND METASTASIS

Saeed Salehin Akhand (8771426) 29 April 2020 (has links)
Breast cancer (BC) is one of the deadliest forms of cancers with high incidence and mortality rates, especially in women. Encouragingly, targeted therapies have improved the overall<br>survival and quality of life in patients with various subtypes of BC. Unfortunately, these first-line therapies often fail due to inherent as well as acquired resistance of cancer cells. Treatment evading cancer cells can exhibit systemic dormancy in patients over a long period of time without manifesting any symptoms. In a suitable environment, these undetected disseminated tumor cells can relapse in the form of metastasis. Therefore, it is essential to understand the mechanisms of<br><div>BC recurrence and to develop durable therapeutic interventions to improve patient’s survival. In this dissertation work, we studied fibroblast growth factor receptors (FGFR), as therapeutic targets to treat the recurrence of drug-resistant and immune-dormant BC metastasis. <br></div><div><br></div><div>The HER2 subtype of BC is characterized by the overexpression of human epidermal growth factor receptor 2 (HER2), which drives elevated downstream signaling promoting tumorigenesis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in which an anti-HER2 antibody targets HER2 overexpressing tumor cells and delivers a highly potent microtubule inhibitor. Using novel models of minimal residual disease (MRD) following T-DM1 treatments, we found that epithelial to mesenchymal transition is a critical process for cells to persist the TDM1 treatments. The upregulation of FGFR1 may facilitate insensitivity to T-DM1. Our data also showed that FGFR1 overexpression in HER2+ tumors leads to a higher incidence of recurrence, and these recurrent tumors show sensitivity towards covalent inhibition of FGFR. <br></div><div><br></div><div>In addition to drug-induced MRD in the primary tumor sites, disseminated tumor cells (DTCs) can demonstrate dormant phenotype via maintaining an equilibrium with immunemediated tumor clearance. Factors affecting such equilibrium may contribute to the recurrence of breast cancers metastasis. We show that such immune-mediated dormancy can be modeled with the 4T07 tumors. These tumors display immune-exclusion phenotypes in metastatic pulmonary organs. The inhibition of FGFR modulates the immune cell compositions of pulmonary organs favoring anti-tumor immunity. However, inhibition of FGFR may also affect T cell receptor downstream signaling, resulting in the inhibition of cytolytic T cell’s function. Finally, we report that combination therapy using the FGFR kinase inhibitor and an immune checkpoint blockade showed effective targeting of metastatic 4T07 tumors. <br></div><div><br></div><div>FGFR signaling as a therapeutic target in various tumors has been an active focus of cancer research. In this dissertation work, we have expanded our understanding of the role of FGFR in the recurrence of drug-resistant breast cancers as well as in the maintenance of an immune evasive microenvironment promoting pulmonary growth of tumors. Moreover, we presented evidence that it is possible to repurpose FGFR targeted therapy alone or in combination with checkpoint blockades to target recurrent metastatic BCs. In the future, our novel models of minimal residual diseases and systemic immune dormancy may act as valuable biological tools to expand our understanding of the minimal residual disease and dormant tumor cells.</div>

Page generated in 0.1096 seconds